Examining the clinical utility of lacosamide: Pooled analyses of three phase IIIII clinical trials

CNS Drugs

Volumn 24, Issue 12, 2010, Pages 1041-1054

  Chung, Steve ^a   Ben Menachem, Elinor ^b   Sperling, Michael R ^c   Rosenfeld, William ^d   Fountain, Nathan B ^e   Benbadis, Selim ^f   Hebert, David ^g   Isojrvi, Jouko ^g   Doty, Pamela ^g  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Comprehensive Epilepsy Care Center for Children and Adults ^*  (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

^g Triangle Medical Research   (United States)

Author keywords

Antiepileptic drugs, therapeutic use; Epilepsy; Lacosamide, therapeutic use

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

AREA UNDER THE CURVE; ARTICLE; ATAXIA; BLURRED VISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIPLOPIA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; FATIGUE; FOCAL EPILEPSY; GRAND MAL SEIZURE; HEADACHE; HUMAN; MAINTENANCE THERAPY; NAUSEA; NYSTAGMUS; PHARMACODYNAMICS; PRIORITY JOURNAL; TREATMENT OUTCOME; TREMOR; VOMITING;

ACETAMIDES; ADULT; ANTICONVULSANTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 78649339546     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11586830-000000000-00000     Document Type: Article

References (22)

1. Bravata DM, Olkin I. Simple pooling versus combining in meta-analysis. Eval Health Prof 2001 Jun; 24 (2): 218-30
2. VIMPAT® (lacosamide): US prescribing information. Smyrna (GA): UCB, Inc. 2008
3. VIMPAT®: summary of product characteristics for lacosa- mide. Belgium: UCB Pharma, S.A. 2008
4. Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007; 13 (1): 21-42
5. Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007 Jul; 48 (7): 1308-17
6. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009 Mar; 50 (3): 443-53
7. Chung S, Sperling MR, Biton V, et al. Lacosamide as ad- junctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010; 51 (6): 958-67
8. Biton V, Fountain NB, Rosenow F, et al. Safety and tolerability of lacosamide: a summary of adverse events in epilepsy clinical trials [abstract]. Neurology 2009; 72 (11 Suppl. 1): A225
9. Beydoun A, D'Souza J, Hebert D, et al. Lacosamide: phar- macology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009 Jan; 9 (1): 33-42
10. Chung SS. Lacosamide: new adjunctive treatment option for partial-onset seizures. Expert Opin Pharmacother 2010 Jun; 11 (9): 1595-602
11. Ben-Menachem E, Chung S, Rudd D, et al. Evaluation of lacosamide efficacy in subjects with partial-onset seizures across the dose range used in phase II/III clinical trials [abstract]. Neurology 2009 Jun 28-Jul 2; 72 (11 Suppl. 1): A329
12. French J, Brodie M, Hebert D, et al. Evaluation of seizure freedom and 75% responder rates with lacosamide in subjects with partial-onset seizures in phase II/III clinical trials. Innsbruck Colloquium on Status Epilepticus; 2009 Apr 2-4; Innsbruck
13. Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia 2007 Jul; 48 (7): 1303-7
14. Sperling M, Rudd D, Hebert D, et al. Early onset of efficacy in the initial weeks of treatment with lacosamide: a pooled analysis of three phase II/III trials. Neurology 2009; 72 (11 Suppl. 1): A352
15. Benbadis S, Elger C, Hebert D, et al. Efficacy of adjunctive lacosamide in patients with partial-onset seizures and prior surgical interventions for epilepsy. American Epilepsy Society (AES) 63rd Annual Scientific Conference; 2009 Dec 4-8; Boston (MA)
16. Rosenfeld WRD, Hebert D, Doty P. Lacosamide efficacy is independent of concomitant AED(s) treatment [abstract]. Neurology 2009; 72 (11 Suppl. 1): A353
17. Schiller Y, Najjar Y. Quantifying the response to anti- epileptic drugs: effect of past treatment history. Neurology 2008 Jan 1; 70 (1): 54-65
18. Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat 2008 Jun; 4 (3): 507-23
19. Chung S. Third-generation antiepileptic drugs for partial- onset seizures: lacosamide, retigabine, and eslicarbazepine. Eur Neurol J 2009; 1 (1): 1-11
20. Cretin B, Hirsch E. Adjunctive antiepileptic drugs in adult epilepsy: how the first add-on could be the last. Expert Opin Pharmacother 2010 May; 11 (7): 1053-67
21. Gil-Nagel A, Zaccara G, Baldinetti F, et al. Add-on treat- ment with pregabalin for partial seizures with or without generalisation: pooled data analysis of four randomised placebo-controlled trials. Seizure 2009 Apr; 18 (3): 184-92
22. Peeters K, Adriaenssen I, Wapenaar R, et al. A pooled analysis of adjunctive topiramate in refractory partial epilepsy. Acta Neurol Scand 2003 Jul; 108 (1): 9-15